Skip to main menu Skip to main content Skip to footer

William C. Christie, MD

Lead Principal Investigator at Scott & Christie Eyecare Associates

William C. Christie, M.D. is the sole owner and President/CEO of Scott & Christie Eyecare Associates. Doctor Christie has been practicing ophthalmology since 1990 and has performed over 30,000 cataract procedures. Besides performing the standard cataract surgery, Doctor Christie offers cutting-edge, multi-focal cataract lens technologies as well as laser cataract surgery. In addition to providing medical procedures, Doctor Christie serves as Principal Investigator and is the founder for The Eye Research Institute.  The Eye Research Institute is one of the largest Clinical Investigator Sites in the country and the world for the research of both ophthalmic devices and pharmaceuticals.

In his personal life, Doctor Christie volunteers his time and expertise both locally and internationally. He is a board member of the Urban Impact Foundation, a Pittsburgh organization devoted to helping disadvantaged youth. Additionally, he has travelled several times to the Manna Mission Hospital in Ghana, Africa to perform cataract surgery for people who otherwise would not have access to vision care. He is also the founder and President of Mission Vision, a non-profit dedicated to providing eye exams and eyewear both internationally and within the Western Pennsylvania Region.

Doctor Christie is a member of the American Academy of Ophthalmology (AAO) and American Society of Cataract and Refractive Surgery (ASCRS).

Awards and Publications

Publications

Publications

  • Christie W, et al. Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients With Open-Angle Glaucoma or Ocular Hypertension. Clinical Ophthalmology 2023:I7 3023-3036.
  • Weinreb R, Christie W, Medeiros F, Craven R, Kim K, Nguyen A, Bejanian M, Wirta D. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes. Ophthalmol Glaucoma, 2023.
  • Chang D, Thompson V, Christie W, Chu Y, Vida R. Clinical Evaluation of a Modified Light Transmission Short-Wavelength Filtering Intraocular Lens Compared to a Colorless Control. Ophthalmol Ther, 2023.
  • Chang D, Janakiraman D, Smith P, Buteyn A, Domingo J, Jones J, Christie W. Visual Outcomes and Safety of an Extended Depth-of-focus Intraocular Lens: Results of a Pivotal Clinical Trial. J Cataract Refract Surg, Mar 2022.
  • Shirneshan E, Wirta D, Christie W, Tauber J, Lee S, Campbell J. Assessing Presbyopia Impacts and Coping Behaviors with a de Novo PRO Instrument in a Phase 4 Study of AGN-190584 (Pilocarpine 1.25%). Invest. Ophthalmol. Vis. Sci. 2021;62(8):2912.
  • Christie W, Tauber J, Jerkins G, Fangqui Z, Tepelus T, Penzner J, Liu H, Safyan E, Robinson M. Gemini 1 Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia. ARVO Congress Presentation, 2021.
  • Christie W, Jerkins G, Tauber J, Fangqui Z, Tepelus T, Safyan E. Gemini I Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia. ASCRS Symposium on Cataract, IOL, & Refractive Surgery Congress Presentation, 2021.
  • Wirta D, Christie W, Tauber J, Shirneshan E, Lee S, Campbell J. Assessing Presbyopia Impacts and Coping Behaviors with a de Novo PRO Instrument in a Phase 3 Study of AGN-190584 (Pillocarpine 1.25%). ASCRS Symposium on Cataract, IOL, & Refractive Surgery Congress Presentation, 2021.
  • Craven E, Walters T, Christie W, Day D, Lewis R, Goodkin M, Chen M, Wangsadipura V, Robinson M, Bejanian M. Bimatoprost SR Study Group. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients. Drugs, Feb 2020.
  • Chang D, Christie W, Loden J, Smith P, Jackson B. Clinical evaluation of a bacterially derived sodium hyaluronate 2.3% ophthalmic viscosurgical device. J Cataract Refract Surg, Dec 2019.
  • Lewis R, Christie W, Day D, Craven E, Walters T, Bejanian M, Lee S, Goodkin M, Zhang J, Whitcup S, Robinson M. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. Am J Ophthalmol, Mar 2017.
  • Walters T, Lewis R, Christie W, Day D, Craven E, Bejanian M, Lee S, Goodkin M, Zhang J, Whitcup S, Robinson M. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. ASCRS ASOA Symposium Presentation, 2016.
  • Jones J, Christie W, Buteyn A. Visual Outcomes of a New Extended Range of Vision IOL. ASCRS ASOA Symposium Presentation, 2016.
  • Lewis R, Christie W, Day D, Craven R, Bejanian M, Lee S, Goodkin M, Zhang J, Robinson M. Bimatoprost Sustained-Release Implants for Glaucoma Terapy: Interim Results From a 24-Month Phase 1/2 Clinical Trial. AAO Poster Presentation, 2015.
  • Modi S, Lehmann R, Walters T, Fong R, Christie W, Roel L, Nethery D, Sager D, Tsorbatzoglou A, Philipson B, Traverso C, Reiser H. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg, 2014 Feb;40(2):203-11.
⇧